Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Rovi and Recordati Deemed Top Picks By Analyst

The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.
Market Intelligence Europe

Switching Studies Show Safety Of Celltrion's Infliximab Biosimilar In IBD

Two infliximab switching studies have provided reassuring data on the safety of Celltrion’s CT-P13 infliximab biosimilar to treat IBD. While one report explores changing pediatric patients to CT-P13 from the Remicade reference drug, the other looks at reverse switching patients from the biosimilar to the originator brand.

Biosimilars Market Intelligence

UK Prices Show Volatility Of Recent Launches

Double-digit rises and falls in the average prices of recently-launched generics recorded by market researcher WaveData demonstrated the volatile pricing dynamics of the UK market in December.

United Kingdom Pricing Strategies

UK Patients Report Concerns With Biosimilar Switching

Patients in the UK are being switched to biosimilars without being consulted or receiving the support they need, a report published by the Patients Association and funded by AbbVie has found. The charity is calling for shared decision-making and collaborative working between patients and clinicians.

United Kingdom Biosimilars

Everolimus SPC Expiries May Not Be End Of The Story

Novartis' everolimus oncology brand, Afinitor, and AstraZeneca's dapagliflozin-based Farxiga diabetes treatment are the focus of January's review of expiring intellectual-property rights, based on IQVIA's Ark Patent Intelligence Database.
Intellectual Property Market Intelligence

Healthcare Providers In US And Europe Remain Cautious About Biosimilars

Healthcare providers in the US and Europe are still cautious about biosimilars due to limited knowledge, low prescribing comfort, and safety and efficacy concerns, according to a review evaluating clinicians’ knowledge, perceptions and prescribing behaviors of such drugs.

United States Europe
See All
UsernamePublicRestriction

Register